A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).

Date Issued

2017

Author(s)

Corrie, Philippa

Qian, Wendi

Basu, Bristi

Jodrell, Duncan Ian

Falk, Stephen

Iwuji, Chinenyu

Wasan, Harpreet

Palmer, Daniel H.

Scott-Brown, Martin

Wadsley, Jonathan

Arif, Seema Safia

Babaoglan, A. Burcu

Dalchau, Katy Marie

Gopinathan, Aarthi

Chhabra, Anita

Machin, Andrea

Tuveson, David A.

Valle, Juan W.

DOI

10.1200/JCO.2017.35.4_suppl.342